Novel monoclonal antibody-based therapies for acute myeloid leukemia

Linde M. Morsink, Roland B. Walter*

*Bijbehorende auteur voor dit werk

    OnderzoeksoutputAcademicpeer review

    11 Citaten (Scopus)


    There has been long-standing interest in using monoclonal antibodies to improve outcomes of people with acute myeloid leukemia (AML). While several candidate therapeutics have failed at various stages of clinical testing, improved survival of some patients receiving the CD33 antibody-drug conjugate gemtuzumab ozogamicin has provided first evidence that monoclonal antibodies have a role in the armamentarium against AML. Over the last several years, work to improve the success of monoclonal antibody-based therapies in AML has focused on the identification and exploration of new antigen targets as much as on the development of novel treatment formats such as use of unconjugated engineered monoclonal antibodies and conjugated antibodies, delivering highly potent small molecule drugs or radionuclides to AML cells. Here, we will provide a brief overview of current efforts with such investigational monoclonal antibody-based therapeutics.

    Originele taal-2English
    Pagina's (van-tot)116-126
    Aantal pagina's11
    TijdschriftBest practice & research clinical haematology
    Nummer van het tijdschrift2
    StatusPublished - jun-2019

    Citeer dit